117 related articles for article (PubMed ID: 20629111)
1. Randomized double-blind placebo-controlled crossover study of caffeine in patients with intermittent claudication.
Momsen AH; Jensen MB; Norager CB; Madsen MR; Vestersgaard-Andersen T; Lindholt JS
Br J Surg; 2010 Oct; 97(10):1503-10. PubMed ID: 20629111
[TBL] [Abstract][Full Text] [Related]
2. Caffeine improves endurance in 75-yr-old citizens: a randomized, double-blind, placebo-controlled, crossover study.
Norager CB; Jensen MB; Madsen MR; Laurberg S
J Appl Physiol (1985); 2005 Dec; 99(6):2302-6. PubMed ID: 16081625
[TBL] [Abstract][Full Text] [Related]
3. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT
Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
Messa GL; Gelso E
Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
[TBL] [Abstract][Full Text] [Related]
5. PoleStriding exercise and vitamin E for management of peripheral vascular disease.
Collins EG; Edwin Langbein W; Orebaugh C; Bammert C; Hanson K; Reda D; Edwards LC; Littooy FN
Med Sci Sports Exerc; 2003 Mar; 35(3):384-93. PubMed ID: 12618567
[TBL] [Abstract][Full Text] [Related]
6. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
Hood SC; Moher D; Barber GG
CMAJ; 1996 Oct; 155(8):1053-9. PubMed ID: 8873633
[TBL] [Abstract][Full Text] [Related]
7. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Kieffer E; Bahnini A; Mouren X; Gamand S
Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
[TBL] [Abstract][Full Text] [Related]
8. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials.
Radack K; Deck C
Arch Intern Med; 1991 Sep; 151(9):1769-76. PubMed ID: 1679624
[TBL] [Abstract][Full Text] [Related]
9. The effects of sublingual glyceryl trinitrate on walking distance in patients with intermittent claudication. A randomised, doubled-blind, placebo-controlled, cross-over study.
Heer R; Walker S; MacSweeney S
Curr Med Res Opin; 2001; 17(2):113-5. PubMed ID: 11759179
[TBL] [Abstract][Full Text] [Related]
10. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation.
De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E
Angiology; 2002; 53 Suppl 1():S7-12. PubMed ID: 11865838
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
Mohler ER; Hiatt WR; Creager MA
Circulation; 2003 Sep; 108(12):1481-6. PubMed ID: 12952839
[TBL] [Abstract][Full Text] [Related]
14. [Padma-28, a herbal preparation, increases walking distance in patients with intermittent claudication].
Drabaek H; Mehlsen J; Petersen JR; Himmelstrup H; Hansen KF
Ugeskr Laeger; 1994 Oct; 156(42):6207-9. PubMed ID: 7998359
[TBL] [Abstract][Full Text] [Related]
15. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications.
Thulesius O; Lundvall J; Kroese A; Stranden E; Hallböök T; Brunes L; Gjöres JE; Akesson H; Einarsson E; Ohlin P
J Cardiovasc Pharmacol; 1987 Jun; 9(6):728-33. PubMed ID: 2442541
[TBL] [Abstract][Full Text] [Related]
16. Beta blockade and intermittent claudication.
Lepäntalo M
Acta Med Scand Suppl; 1985; 700():1-48. PubMed ID: 2865873
[TBL] [Abstract][Full Text] [Related]
17. The effects of physical training and flunarizine on walking capacity in intermittent claudication.
Lepäntalo M; Sundberg S; Gordin A
Scand J Rehabil Med; 1984; 16(4):159-62. PubMed ID: 6397852
[TBL] [Abstract][Full Text] [Related]
18. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
[TBL] [Abstract][Full Text] [Related]
19. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial.
De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E
Angiology; 2002; 53 Suppl 1():S13-7. PubMed ID: 11865829
[TBL] [Abstract][Full Text] [Related]
20. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
